

The Role of microRNAs Regulated Breast Cancer Stem Cells in the Pathogenesis, Prognosis and Aggressiveness of Breast Cancer

ABSTRACT

Breast cancer is a leading cause of cancer related death among women worldwide and it is a complex disease characterized by its heterogeneity. The heterogenous characteristic of the breast cancer is responsible for its aggressiveness and treatment resistance. Breast cancer stem cells (BCSCs) are population of heterogenous cells with increased propensity for proliferation, differentiation, migration, invasion and mammosphere formation with increased resistance to treatment. They have ability to initiate and propagate cancer cells population and share similarity with the normal stem cells in relation to their expressions of cell surface markers; Cluster of Differentiation 44 positive (CD44⁺), Cluster of Differentiation 24 negative/low (CD24^{-low}) and Alkaline dehydrogenase 1 (ALDH1).

MicroRNAs (miRNAs) are responsible for the RNA silencing and post-transcriptional regulation of the gene expression. MicroRNAs (miRNAs) control gene expression by acting as oncogenes or tumor suppressor genes. The epigenetic mechanisms are used for the regulation of miRNAs expression in the breast cancer, and this can be targeted to reverse the cancer progression. This review aims to provide an overview of the pathogenic mechanism of the microRNA's expressions on the breast cancer stem cells in controlling the prognosis and aggressiveness of breast cancer disease. This is done by highlighting the regulatory mechanism of miRNA expressions on the BCSCs.

Dysregulation of the MicroRNAs expression in the breast cancer stem cells and upregulated miRNAs expression were identified in the breast cancer stem cells (BCSCs), including miR-10b, miR-21, miR-155, miR-181, miR-183, miR-210 and miR-221/222, and the downregulated miRNAs expression in BCSCs include Let-7, miR-22, miR-30e, miR-31, miR-103/107, miR-200, miR-205, miR-335, miR-449a, miR-519c, miR-600, miR-708, miR-760. Studies showed association between the miRNA expression and breast cancer metastasis and aggressiveness. MicroRNAs were noticed to have a regulatory effect on neovascularization, drug resistance, and cancer metastasis. They can be used as predictive indicators in determining prognosis of breast cancer following cancer treatment and miRNAs expression can be used to determine the metastatic BCSCs for an efficient targeting mechanism and

identification of the metastatic cancer cells. The systematic literature review aims at providing insight into the potential roles of microRNA in oncology especially breast cancers. The data for this study review were obtained from the Medline on OvidSP, includes PubMed of the US National Library of Medicine and the search was done through the University of Bristol Library services. This is to provide an overview of the pathogenic mechanism of microRNAs regulatory effect on the breast cancer stem cells in controlling the prognosis and aggressiveness of breast cancer disease. The review will be providing highlight of the dysregulation of oncogenic and tumor suppressor microRNAs in the breast cancer stem cells and highlighting the roles of miRNAs regulated BCSCs in the pathogenesis, prognosis, and aggressiveness of the breast cancer. We further discuss the biogenesis of miRNAs, regulatory roles of miRNAs on BCSCs, and then summarize the mechanism of miRNAs regulated BCSCs.

Key words: microRNAs, Breast cancer stem cells, epigenetic mechanism, dysregulation, breast cancer aggressiveness, cell surface markers.

ABBREVIATIONS

miRNAs: MicroRNAs. BCSCs: Breast cancer stem cells. HER2⁺: human epidermal growth factor 2⁺. BRCA: Breast cancer type 1 (type 2 (BRCA2), ATM: Ataxia-Telangiectasia Mutated gene. PTEN: Phosphatase and tensin homolog genes. Ubc9: Ubiquitin conjugating enzyme 9. ITGB3: integrin b3gene. miR: microRNAs. CSCs: Cancer stem cells. H-RAS: Harvey rat sarcoma oncogene.

1. INTRODUCTION

Breast cancer is a leading cause of cancer related death among women worldwide particularly in the developed worlds. It is a complex disease characterized by its heterogeneity with variation in its molecular and genetic composition [1]. The heterogeneous characteristic of the breast cancer is responsible for its aggressiveness and treatment resistance. Breast cancer disease has different molecular subtypes based on their gene expression and these include human epidermal growth factor 2⁺ (HER2⁺), luminal and basal-like subtypes of breast cancer disease. HER2⁺ subtype is associated with amplification or overexpression of epidermal growth factor (EGF) oncogene, luminal subtype expresses hormone receptors (estrogen and progesterone receptors), and the basal-like subtype lacks HER2 and hormone receptors (triple

negative). Inheritance germ line gene mutations had also been implicated in the etiopathogenesis of breast cancer disease and these include Breast cancer type 1 (BRCA1), type 2 (BRCA2), Ataxia-Telangiectasia Mutated (ATM) gene and Phosphatase and tensin homolog (PTEN) genes. [1]

Breast cancer stem cells (BCSCs) are population of heterogeneous cells with increased propensity for proliferation, differentiation, migration, invasion and mammosphere formation with an increased resistance to treatment. Breast cancer stem cells are self-proliferative in nature with ability to initiate and propagate cancer cells population. They share similarity with the normal stem cells in relation to their expressions of cell surface markers including Cluster of Differentiation 44 positive (CD44⁺), Cluster of Differentiation 24 negative/low (CD24^{-low}) and Alkaline dehydrogenase 1 (ALDH1) and BCSCs are characterized based on their tumor initiating and the differentiation capability. [1][2]

MicroRNAs (miRNAs) are non-coding single stranded fragments of RNA molecules, consisting of 20-22 nucleotides and are responsible for the RNA silencing and post-transcriptional regulation of gene expression, through base pairing with the complementary sequences within the mRNA molecules. MicroRNAs are involved in the stem cell replication, differentiation, and apoptosis by controlling the expression of oncogenes and tumor suppressor genes. Dysregulation of microRNAs expressions had been identified in breast cancer stem cells (BCSCs) and some of the identified microRNA expressions that were found to be upregulated in the BCSCs include miR-10b, miR-21, miR-155, miR-181, miR-183, miR-210 and miR-221/222 and the downregulated miRNAs expressions are Let-7, miR-22, miR-30e, miR-31, miR-103/107, miR-200, miR-205, miR-335, miR-449a, miR-519c, miR-600, miR-708, and miR-760 [2][3] Thus, these miRNAs regulate the gene expression in cancer stem cells by acting as either an oncogene or tumor suppressor genes. [3] [4]

A better understanding of mechanism of the regulation of BCSCs by microRNAs in the breast cancer can be extremely useful in determining the pathogenesis, prognosis, and aggressiveness of the breast cancer and important in the formulation of an effective treatment regimen for the breast cancer disease.[5][6][7][8] Numerous studies have been performed on the regulatory effects of microRNA expression patterns in the human diseases, but only a few of these studies highlighted the regulatory roles of the miRNAs on breast cancer stem cells in the relation to breast cancer prognosis and the aggressiveness. [9][10][11] The focus of our

study is to highlight the roles of miRNAs in regulating the breast cancer stem cells to understand the pathogenesis, prognosis, and aggressiveness of the breast cancer disease. [10] This is to provide an overview of the pathogenic mechanism of microRNAs regulatory effect on the breast cancer stem cells in controlling the prognosis and aggressiveness of breast cancer disease. This will be done by providing highlight of the dysregulation of oncogenic and tumor suppressor microRNAs in the breast cancer stem cells and highlighting the roles of miRNAs regulated BCSCs in the pathogenesis, prognosis, and aggressiveness of the breast cancer. We would discuss the biogenesis of miRNAs, regulatory roles of miRNAs on BCSCs, and then summarize the mechanism of miRNAs regulated BCSCs.

2. DYSREGULATION OF MicroRNAs in the BCSCs

2.1. Downregulated (Tumor suppressor) MicroRNAs in the BCSCs

2.1.1. Let-7 Family

Let-7 family are tumor suppressor genes that are downregulated in breast cancer stem cells and regulate the expression of BCSCs. The downregulation of Let 7 is associated with the formation of breast cancer. [12][66] Let 7 is a tumor suppressor gene, but they are also found to have anti- apoptotic properties for the regulation of cell differentiation and apoptosis. Let 7 role in the BCSCs include formation of cancer and mesenchymal cells differentiation. The lentiviral mediated re-expression of Let 7 was found to be associated with the reduction in mammosphere formation, reduction in the rates of proliferation, and decreased in the numbers of undifferentiated stem cells, while the reduction in level of Let-7 expression were found to inhibit the differentiation of BCSCs and maintaining their proliferation .[12]

Let 7 is a potential target for anti- cancer therapy in the treatment of breast cancer. Lin 28 is an RNA binding protein that was found to control the Let 7 family and the expression of Lin 28 blocks the formation of Let 7 by promoting the cell proliferations and increasing the formation of cancer cells. Reduction in the level of Let 7 expression would inhibit the BCSCs differentiation, maintaining their proliferation, and promoting the epithelial to mesenchymal cell transformation. Thus, suppression of the Let 7 expression through Lin 28 would promote the formation of breast cancer cells. [12][13]

Let 7 targets the RAS proto-oncogene and high mobility group AT-Hook 2 (HMGA2) genes to inhibit the proliferation and metastasis of the cancer cells. It engages the HMGA2 gene in the differentiation of the epithelial to mesenchymal cell transformation and result in an increased expression of the mesenchymal cell markers. Inflammatory cytokines activate the signal transduction pathway and stimulate the STAT transcription factor 3 (STAT 3) to promote the Lin 28 transcription by causing the repression of Let 7 expression and the upregulation of Let 7 would target the HMGA2. [12][13]

2.1.2 miR-200 Family

The miR-200 family are downregulated in breast cancer stem cells by targeting the Bmi-1 and Suz12 genes. They were found to be involved in the regulation of epithelial to mesenchymal transformation (EMT), self-renewal, clonal expansion, and differentiation of the BCSCs. They comprised of five members in their family (miR-200a, miR-200b, miR-200c, miR-141 and miR-429) and they are grouped into 2 clusters; MIR-200a, miR-200b/miR-429 genes are clustered on chromosome 1 and miR-200c/miR-141 genes clustered on chromosome 12. The miR-200 family expression in the BCSCs and the CD44⁺, CD24^{-low} lineage expressions were compared in the BCSCs, and the findings revealed downregulation of the expressions in the clusters of miRNAs. MiR-200c were found to inhibit the proliferation of the BCSCs by inhibiting the cell growth and promoting cell differentiation. [2][14]

Expressions of some of the miR-200 family were found to be inhibitory to the EMT induced by a transforming growth factor- β (TGF- β) and targeting the repression of E-cadherin through a transcriptional repressor gene Zinc finger E-box binding homeobox 1 (ZEB1) and ZEB2. [15][16] The transcription of miR-200C and miR-141 were found to be a strong inducer for the epithelial differentiation and suppression by the ZEB1 resulting in the epithelial to mesenchymal transformation. Histone modification of the DNA promoter methylation epigenetically regulate the expression of miR-200 and transactivate the p53 in the miR-200c promoter. [17][18][19] Thus, the loss of p53 would result in reduction of the levels of miR-200c. The increase in EMT and the levels of stem cell marker expression were found to be associated with the associated risk of high-grade tumor formation. [20]

MiRNAs	Targets	Function	Reference
--------	---------	----------	-----------

MiRNAs	Targets	Function	Reference
Let-7	RAS, HMGA2	Inhibits proliferation and metastasis	[11][12]
miR-708	Rhodopsin	Decreases migration and metastasis	[16]
miR-103/107	CDK5R1	Decreases migration	[20][21]
miR-200	ZEB1, ZEB2	Inhibits invasion and survival	[13][15][22]
miR-519c	HIF-1 α	Decreases angiogenesis	[12]
miR-31	Radixin, RhoA	Inhibits metastasis and invasion	[13]
miR-335	SOX4, TNC	Inhibits metastasis and invasion	[13][23][24]
miR-30e	ITGB3, UBC9, p53	Prevents tumorigenesis	[12]
miR-205	HER3	Inhibits proliferation	[22][25][26]
miR-22	E α , Sp1, C-MYC	Inhibits proliferation, invasion, and metastasis	[17][18]
miR-449a	PLAGL2	Inhibits proliferation and metastasis	[27]
miR-600	SCD1	Reduces BCSC self-renewal and tumorigenicity	[28]

MiRNAs	Targets	Function	Reference
miR-760	NANOG	Inhibits proliferation and migration	[5][29][42]

TABLE 1: TUMOR SUPPRESSOR MicroRNAs

2.1.3 miR-30 Family

MicroRNA 30 family are downregulated in BCSCs, most commonly miR-30e. They were found to modulate the self-renewal and anti-apoptotic properties of BCSCs. The expression of miR-30e in the breast cancer stem cells would result in the inhibition of cell proliferation by decreasing the levels of Ubiquitin conjugating enzyme 9 (Ubc9) and induced apoptosis through repression of the integrin $\beta 3$ gene (ITGB3). The blocking of miR-30e expression in the differentiated breast cancer stem cells would result in the proliferation of the cancer cells. AVEN anti-apoptotic protein are downregulated after overexpression of the miR-30 confirming the involvement of miR-30 family in the regulation of genes for the non-attachment proliferation of mammospheres formation and in the apoptosis of BCSCs. [30] [31] [32]

2.1.4 .miR-708

The expressions of miR-708 are downregulated by the polycomb suppressor complex 2 induced H3K27 trimethylation in the breast cancer by targeting neuronatin to reduce the activation of focal adhesion kinase (FAK) resulting in decrease cell migration and cancer metastasis. MiR-708 expressions are suppressed by targeting rhodopin. Thus, the study showed an overexpression of Neuronatin result in resistance to miR-708 suppression with a decrease cell migration and metastasis. MiR-708 has a repressive metastatic effect in the breast cancer and this could have a potential role in the treatment of metastatic cancer. [16]

2.1.5. miR-22

MicroRNA-22 overexpression decrease the (estrogen receptor α (E α) gene by promoting the cleavage of mRNA targeted by the 3'UTR and resulting in the inhibition of proliferation, invasion, and metastasis [17]. The overexpression of miR-22 would reduce the metastasis, invasion, and proliferation of BCSCs. [18] A study revealed that miR-22 would decrease the expression of cluster of differentiation 147 (CD147), which is an extracellular matrix metalloproteinase inducer and associated with cancer growth, invasiveness, and metastasis. CD147 downregulates the specific protein 1 (Sp1) gene expression and the miR-22/Sp1/C-myc network have a regulatory effect on the transcription of CD147 gene to reduce the invasive and metastatic ability of the BCSCs. Frankel et al in 2008 revealed that tumor suppressor protein programmed cell death 4 (PDCD4) are regulated by miR-21 in the BCSCs while another study by Wickramasinghe et. al in 2009 revealed reduction in the level of expression of miR-21 in the BCSCs by estradiol E2. [19][21]

2.1.6. miR-103/107

Overexpression of miR-103/miR-107 and the silencing of cyclin dependent kinase 5 activator 1 (CDK5R1) gene would reduce the migration of cancer cells.[20] These are found to modulate the expression of CDK5R1 and affect the effect of Cyclin dependent kinase 5 (CDK5) and their pathway.[20] [21]

2.1.7. miR-205

miR-205 are downregulated in breast cancers and they interfere with the HER receptor by suppressing the proliferation of cells. MiR-205 targets the HER3 receptor to inhibit the activation of Akt mediators. They are downregulated in the stem cells that have undergone EMT in response to TGF- β . [15] Ectopic expression of miR-205 in the BCSCs would result in the suppression of cancer cell proliferation, invasion, and tumor growth by targeting Her3 and VEGF-A genes. A study showed that miR-205 expression would enhance cancer responsiveness to therapy by targeting Her3 gene and interfere with the PI3K/Akt survival pathway to improve the responsiveness to tyrosine kinase inhibitors.[22] MiR-205 can act as a tumor suppressor gene through p53 and re-expression would result in decreased cell proliferation and cell cycle arrest.

2.1.8 miR-335

The expression of miR-335 are downregulated in the BCSCs were found to be associated with reduced cancer cell invasion, migration, and metastatic ability.[23] It was noted that Tenascin-C (TNC) which is an extracellular matrix protein, and transcription factor SOX4 oncogene targeted the miR-335.[24]

Study revealed that miR-31 targets radixin, RhoA, and integrin-5 genes to promote metastasis and spread of the breast cancer. The overexpression of miR-31 resulted in the decrease expression of targeting genes and reduced breast cancer metastasis and the invasiveness. [25]

2.1.9. miR-519c

miR-519c regulate neovascularization by targeting the hypoxia inducible factor- 1 α (HIF-1 α) to regulate the neovascularization in the breast cancer cells by the stimulation of VEGF (vascular endothelial growth factor), basic fibroblast growth factor, and interleukin-8. A study revealed decreased angiogenesis due to the overexpression of miR-519c. [26]

2.1.10. miR-449a

A research study revealed overexpression of miR-449a suppressed the proliferation and metastasis of breast cancer by targeting the Pleomorphic adenoma gene like 2 (PLAGL2) gene. The miR-449a levels were found to be decreased in the breast cancer cells. [27]

2.1.11. miR-600

Overexpression of miR-600 inhibit the production of WNT proteins and promote the breast cancer stem cells differentiation. [28] Study showed that expression of miR-600 would regulates the BCSCs colony. The level of expression of miR-600 is associated with the survival of the patient with the breast cancer. The upregulation of miR-600 regulates the WNT signaling pathway by suppressing the stearyl-CoA desaturase-1 expression. The WNT signaling pathway is active and promotes proliferation of cells in the absence of miR-600. [28][35]

2.1.12. miR-760

MiR-760 targets the NANOG gene to inhibit the proliferation and migration of breast cancer cells. [29]

2.2. Upregulated (Oncogenic) miRNAs in the BCSCs.

2.2.1. miR 181 Family

MiR-181 are upregulated in the breast cancer stem cells. The increase level of expression of miR-181 in the BCSCs initiated the mammosphere formation .[30] Study revealed the effect of transforming growth factor β mediated by miR-181 on the BCSCs would increase the proliferation of cells.[11] The up-regulation of the miR-181 were identified to be an inducer for the mammosphere formation at the post-transcriptional level by the TGF- β and identified BRCA1 as the targeted gene .[31] Ataxia telangiectasia (ATM) can also act as a tumor suppressor gene to reduce the mammosphere formation.

2.2.2. miR-183

miR-183 expression was associated with the estrogen receptor and HER2/neu receptor to dysregulate the invasion and migration of the cancer cells. Study showed miR-183 targeted VIL2-coding protein Ezrin and have a target for the early growth response protein 1 (EGR1) mRNA. [32]

2.2.3. miR-210

The expression of miR-210 in the breast cancer was associated with the level of hypoxia and its overexpression was stimulated by hypoxia (HIF-1 α and Von Hippel Lindau dependent factor). The level of miR-210 was found to be inversely related to the survival of the patient with breast cancer. Thus, they can be used as a prognostic indicator and predictive index for breast cancer. [33]

2.2.4. miR-10b

miR-10b were noticed to be highly upregulated in the breast cancer and study revealed the miR-10b expressions were associated with the metastasis, invasion, and migration of the breast cancer cells .[34] Thus, the level of miR-10b expression associated with the metastatic ability of the cancer .[35] E-cadherin are found to have a potential in targeting the miR-10b with the associated increase in the tumor size, tumor grading, stage, proliferation, metastasis, and level of expression of Her2 expressions .[36] Transcription factor twist can induce the miR-10b and promote the cancer invasion and metastasis by targeting the homeobox D10 (HOXD10) gene.

Oncogenic miRNAs	Targets	Function	Reference
miR-10b	ZEB1, PIK3CA	Promotes EMT, metastasis, and proliferation	[36]
miR-21	PTEN, PCDC4, TPM1, TIMP3	Promotes metastasis and tumor growth	[2][12][37]
miR-155	TP53INP1	Promotes proliferation, Prevents apoptosis	[9]
miR-181	BRCA1	Promotes tumor growth	[30]
miR-183	VIL2, EGR1	Promotes migration and metastasis	[32]
miR-210	Efna3, Ptp1b	Decreases survival	[33]
miR-221/222	P27Kip1, p57, TRPS1, PTEN	Enhances proliferation and invasion	[38][41][42]

TABLE 2: Oncogenic MicroRNAs

2.2.5. miR-21

MiR-21 expressions were associated with the migration and invasion of breast cancer stem cells. This was implicated in the progression and metastasis of breast cancer. The expression of miR-21 found to be associated with the bad prognosis.[37] They are located on chromosome 17q23.1 and primary miRNAs in the humans.[38] Study showed HIF-1 α and miR-21 were up-regulated in the BCSCs and decrease level of their expression would result in the reversal of the epithelial to mesenchymal transformation. Thus, reduce expression of HIF-1 α will reduce the cancer cells migration and invasiveness. [29]

Decreased expression of miR-21 would inhibits cancer growth by targeting the Programmed cell death 4 (PDCD4), metalloproteinase inhibitor 3 and alpha-tropomyosin 1. [2] PDCD4 and p53 are the targets for the miR-21. Mammary serine protease inhibitor (Maspin) suppresses the invasion and metastasis of breast cancer cells by reducing their ability to invade, induce apoptosis and neovascularization. Thus, PDCD4 and Maspin were targeted by miR-21 for cancer invasion and metastasis. Study identified a tumor suppressor tropomyosin 1 (TPM1) as a target for miR-21 and showed negative correlation with the expression of miR-21 and PTEN in the BCSCs related to the cancer advanced stage, metastasis, and poor survival.[39] Transforming growth factor- β upregulate the expression of miR-21 with associated increased risk of high-grade tumor and negative hormone receptor status.

2.2.6. miR-221 and miR-222

Upregulation of miR-221 and miR-222 increase the ability of the cancer cells invasion and migration.[40] They are found to suppress the target protein Tricho-rhino-phalangeal syndrome type 1 protein which is a ZERB 2 GATA family. [41]

MiR-221 and miR-222 are expressed more in the basal type of breast cancer and their suppression in the p57 and p27/Kip1 proteins result in the decreased cell cycle and increase proliferation. [13] They increase tumor growth by targeting the PTEN. [42] MiR-222 were noticed to be overexpressed in the BCSCs and they can be used as a marker in the differentiation of BCSCs from the normal progenitor stem cells.

2.2.7. miR-155

miR-155 are overexpressed in the breast cancer and associated with the metastasis, diagnosis, and prognosis of the breast cancer .[43][44] Study showed inflammation and hypoxia increase the level of miR-155 expression .[45] Tumor protein p53 inducible nuclear protein 1 (TP53INP1) in Michigan Cancer Foundation-7 (MCF-7) cells identified as the target for the miR-155 and overexpression of the miR-155 increase the cancer cell migration and elicits anti-apoptotic effect by inhibiting the caspases-3,8,9 and p21 through suppression of TP53INP1 in MCF-7 cells.

3. MicroRNA regulated BCSCs in the Pathogenesis, Dysregulation, Prognosis and Aggressiveness of Breast Cancer.

The overexpression of the miR-125 target the pro-apoptotic gene Bcl-2 antagonist killer 1 in the breast cancer resulting in the tumor advancement and metastasis. Problem with the apoptosis are associated with the malignant advancement of the breast cancer.[46][47] miR-195, miR-24-2 and miR-365 target and suppress the Bcl-2 gene resulting in the activation of apoptosis in hormone dependent BCSCs.[48] miR-21 inhibits tumor suppressor gene PTEN and formed the death inducing signaling complex (DISC complex) in the breast cancer .[49] miR-141, miR-200b and miR-200c target the B lymphoma Mo-MLV insertion region 1 homolog (Bmi1) gene to suppress the p53 leading to the programmed cell death via the ARF tumor suppressor (p19Arf) gene. Lerner et. al in 2012 revealed that miR-200c would induce apoptosis by targeting Noxa pro-apoptotic gene (Bcl-2 family) and Fimbriae associated protein 1 (FAP-1) (inhibitor of CD95).

MiR-145 are downregulated in breast cancer. [22][50] This could be used as a diagnostic marker for an early cancer detection. [51][52] Spizzo et. al in 2010 demonstrated the pro-apoptotic effect of miR-145 with the activation of TP53 stimulating the expression of miR-145 and enhancing the pro-apoptotic effects. MiR-145 targets the ER- α gene to promote apoptosis and induce p53 transcription of the miR-145. MiR-145 targets and controls N-RAS and VEGF-A at the post-transcriptional level to inhibit the neovascularization, growth, and cancer cell invasion. [52] [53]

MiR-21, miR-126, miR-155, miR-199a and miR-335 were found to be associated with the histologic tumor grading of breast cancer and expression status of the sex hormone receptors. Research study revealed that miR-21 concentrations can be used to distinguish normal healthy stem cells from the breast cancer stem cells.[52] Thus, this can be useful in distinguishing the local regional spread from the distant metastasis. Upregulated levels of miR-214 and miR-218 will distort the cell cycle by suppressing the proliferation of cancer cells and promoting the programmed cell death. [54] overexpression of miR-621 inhibit the expression of F-box protein 11 (FBXO11), which is its targeting gene, and increase the activity of p53 by promoting apoptosis in the breast cancer stem cells and increase the responsiveness to the chemotherapy.[54] MiR-621 can be used as a prognostic indicator in the treatment of breast cancer. Thus, the higher the expression of miR-621 the better the prognosis. MiR-621

increases the sensitivity to paclitaxel plus carboplastin (PTX/CBP) chemotherapy by inhibiting the FBXO11 to increase the activity of p53 and promoting apoptosis.[54]

The miR-128 are downregulated and reduced in the BCSCs when polycomb ring finger oncogene BMI-1 and the ABCCS (ATP binding cassette sub-family C member) genes were targeted. MiR-128 expression associated with the resistance to cancer therapy and can be used to predict the survival following treatment. The overexpression of miR-128 decreased the levels of BMI-1 and ABCCS genes in the BCSCs and promoted the apoptosis and DNA damage following treatment with doxorubicin while the under-expression of miR-128 in the BCSCs was associated with the resistance to chemotherapy. [54]

The miR-495 upregulated in the breast cancer stem cells by targeting the REDD1 gene and overexpression of miR-495 promote the colony formation. Study with the associated clusters of breast cancer stem cells using PROCN⁺/ESA⁺ instead of CD44⁺/CD24^{-low} cells revealed overexpression of miR-495 would down-regulate the expression of E-cadherin and result in an increase cancer invasion. MiR-495 targets the REDD1 to enhance the hypoxia resistant cell proliferation through the post-transcription mechanism.

MiRNAs	Targets	Function	Reference
miR-125	BCL-2	Inhibits tumor advancement and metastasis	[46]
miR-195	BCL-2	Activation of apoptosis	[47]
miR-242	BCL-2	Activation of apoptosis	[48]
miR-365	BCL-2	Activation of apoptosis	[48]
miR-21	PTEN	Induce apoptosis	[49]

MiRNAs	Targets	Function	Reference
miR-141	P53	Activation of apoptosis	[50]
miR-200b, 200c	Noxa, FAP-1	Activation of apoptosis	[50][65]
miR-145	ER- α , Tp53	Inhibits neovascularization, growth, and cancer cell invasion	[50]
miR-621	FBXO11	Promotes apoptosis	[54][60]
miR-128	BMI-1, ABCC5	Predicts survival	[54]
miR-495	REDD1	Promote colony formation	[55]
miR-33b	HMGA2, SALL4, Twist1	Predicts invasion and metastasis	[56][60]
miR-199a	FOXP2	Predicts invasion and metastasis.	[56]
miR-20a	NKG2D	Predicts invasion and metastasis.	[55][56]
miR-34c	Notch 4	Predicts invasion and metastasis.	[55][56]
miR-7	SETDB1	Predicts invasion and metastasis.	[55][56]
miR-9	STAT3	Predicts invasion and metastasis	[55][56]

TABLE 3: MicroRNA regulated BCSCs in the Pathogenesis, Prognosis and Aggressiveness of Breast Cancer

Research study revealed a variation in the expression of BCSCs at primary tumor site from the secondary metastatic region.[2] MiR-33b were found to be targeting HMGA2, SALL4 and Twist1 for the inhibition of cancer cells migration, invasion, and metastasis. MiR-199a promote the cancer cells initiation, propagation, and metastasis but inhibiting the FOXP2 expression.[54] [55][56] miR-20a downregulate the ligands of NKG2D (MICA and MICB) which are the activators of NK (Natural killer) cell receptor in the BCSCs. Wang et. al in 2014 revealed NKG2D promotes the cancer cells metastasis by increasing the BCSCs resistance to natural killer cell cytotoxicity. [55][56] [57]

The p53 tumor suppressor gene was identified as the target for the miRNA-34. [54][58]The downregulation of the miR-34c in the breast cancer stem cells target the Notch 4 gene and the genetic ablation of the miR-34a was noticed to promote the generation of induced pluripotent stem cells (IPSC) without compromising the proliferative and the differentiative properties of the IPSCs. [55][56] MiR- 34c inhibits cancer cell invasion, proliferation and promotes apoptosis. The reduced expression and downregulation of the miR-34c through hyper-methylation of the promoter region of BCSCs would result in an increase proliferation and EMT. [55][56] [59]

miR-7 was found to prevent the metastasis of breast cancer stem cells by targeting the SETDB1 and blocked the expression of c-myc, Twist, and miR-9 by targeting the STAT3 pathway. [3][58][59] Metastatic breast cancer cells expressed high level of osteoblast related genes and increase the chances of breast cancer metastasis to the bone. [55][60][61] Croset et al in 2015 revealed that the miRNAs regulation of the differentiation of osteoblast and their action as a bone metastasis regulator. Reduced expression of miR-340 resulted in the rapid progression and metastasis of the breast cancer. [[60] [61] [62] Thus, increase level of expression of miR-340 can be useful in the suppression of breast cancer progression and metastasis. [54] [55] [56] [60] [62]

3.1. MicroRNAs Biogenesis

MicroRNAs were first discovered in *Caenorhabditis elegans* and described by Lee et al. in 1993. [4] The genes are transcribed in the nucleus into primary miRNAs (Pri-miRNA) by RNA polymerase II. Drosha enzyme cleaves the Pri-miRNAs to precursor miRNAs (Pre-miRNAs) which are hairpin like structures. The Pre-miRNA are cleaved in the cytoplasm by dicer to form a mature miRNA. One strand of the miRNA is associated with the RNA-induced silencing complex (RISC). The miRNAs regulate gene expression through cleavage

of mRNA by binding to the 3'-untranslated regions (3'-UTR) of the target messenger RNAs (mRNAs) through base pairing and this results in cleavage of the target mRNA. [4]The complete complementarity between the miRNA and 3' UTR recognition site will result in the degradation of mRNA and incomplete complementarity will lead to repression of translation. Thus, miRNAs modulate expression of the target genes by degrading their target mRNA or inhibition of the translation through pairing of their sequence with the complementary bases of the target mRNA. [4]




FIGURE 1: MicroRNAs biogenesis.

3.2. BREAST CANCER STEM CELLS (BCSCs)

BCSCs are a small fraction of normal stem cells with self-renewable properties such as high proliferative, and differentiative capability. [5] [63] The epigenetic mechanisms are vital for the generation of cancer stem cells by transforming normal stem cells to cancer stem cells, leading to loss of their differentiation capability by upregulating genes for stem cell replication and downregulating genes for differentiation. [6]




Figure 2: Adapted schematic illustrating carcinogenesis, arising from stem cells, progenitor cells and differentiated cells.

Cancer stem cells (CSCs) have the capacity to generate colonies of cancer cell progeny and share similar characteristics and properties with the normal stem cells such as marker expressions, proliferation, and self-renewable capability. Cancer stem cells are found to be resistant to treatment and can be associated with the initiation, progression, maintenance, and cancer recurrence. Thus, CSCs initiation capacity and resistance to treatments are major contributor to the cancer aggressiveness. Localized breast cancer is considered a manageable disease and majority of patients die from local disease that has spread to other sites in the body.[7] Thus, as miRNAs play a role in breast cancer cell metastasis, they have been implicated as one of the major contributors of death from breast cancer.[7][62][63]

Breast cancer stem cells (BCSCs) were first described in a publication in 2004. [8][64] They were identified and isolated based on their cell surface marker expressions $CD44^{+}$, $CD24^{-/low}$ and epithelial surface antigen (ESA). The expression of high levels of aldehyde dehydrogenase 1 (ALDH1) on BCSCs and the analysis of CD44 and ALDH1 on the cells in the serum showed high level of CD44 expressions were associated with reduced cancer survival when compared to the low serum expression of CD44. [9][64] Thus, CD44 is a cell surface antigen that is important for cell-to-cell interaction, migration, and adhesion.

The activation of epithelial to mesenchymal cell transformation are responsible for the tumor initiating capability of the cancer stem cells with the loss of E- cadherin and cell to cell interactions. Mutations are implicated as the cause of the transformation of normal stem cells into the cancer stem cells (CSCs) and research theory identified (misplacement somatic stem cell theory) problem with the somatic cells positioning as the mechanisms for the formation of CSCs.[10][11][63]

3.3. MicroRNAs Regulatory roles in BCSCs

The regulatory role of microRNAs in breast cancer was first described in 2007 by Yu et. al. where the expression of miRNAs in breast cancer stem cells were compared with the miRNAs from the self-proliferating and differentiating cells of the breast cancer cells. [12][62] MiRNAs are involved in the regulation of the expression of stem cell markers with the activation of the signaling pathways and the transcription of the breast cancer stem cells controlling cell proliferation, migration, survival, apoptosis, tumor growth, cell cycle progression, neovascularization, epithelial to mesenchymal transformation (EMT) and the stem cells maintenance.




Figure 3: Adapted illustration showing the microRNAs Regulatory roles in BCSCs and tumorigenesis.

MicroRNAs are found to play vital role in cancer initiation, progression, and prognosis. The regulatory role of miRNAs on the cancer stem cells by targeting the signaling pathways, including Notch gene, WNT/ β -Catenin, phosphatidylinositol 3-kinase B (PI3)/AKT and nuclear factor kappa-light-chain-enhancer of activated B (NF-Kb) have been implicated in the cancer stem cell proliferation, migration, cell survival, differentiation, invasion, metastasis, and cancer recurrence. [12][13][62][63][65]

Shimono et. al. in 2009 identified miRNA expression in BCSCs and non-cancerous stem cells, including miR-200, let-7, miR-1 and miR-27. The miR-200 family are important for preserving the stem cells, let-7 for inhibition of self-renewal and differentiation by targeting the H-RAS (Harvey rat sarcoma oncogene) and High mobility Group AT-Hook 2 (HMGA2) genes while miR-1 suppresses migration and proliferation of BCSCs by targeting the Wnt pathway. MiR-27 were noticed to upregulate VEGF (vascular endothelial growth factor) in BCSCs to promote neovascularization and metastasis. [6][13][66][67] A study revealed that miR-27 targets the phosphodiesterase family 1 to regulate the drug resistance effects of the BCSCs. [13] [14] Thus, miRNAs can function as an effective therapeutic target for the management of breast cancer through the re-expression of the downregulated miRNAs in the breast cancer stem cells.[61][67][68]

MiR-204, miR-200c, miR-34a, and miR-10b target the self-renewal and epithelial to mesenchymal transformation (EMT) pathways by increasing the survival of the breast cancer stem cells via upregulation of the octamer-binding transcription factor 4 (OCT4), Sex determining region Y box 2 (SRY/SOX2), Kruppel like factor 4 (KLF4), Cellular myelocytomatosis oncogene (C-MYC), Notch homolog 1 translocation associated (NOTCH 1), Zinc finger protein (SNAIL), Zinc finger E-box binding homeobox 1 (ZEB1) and Cadherin 2 (CDH2).[67][68] These genes are targeted in the regulation of pluripotency of the Mitogen activated protein kinase (MAPK), Wingless related integration site (WNT), Hedgehog, Tumor protein 53 (p53) and the Transforming growth factor β (TGF- β) pathways providing major insights to the potential role of targeting the core regulatory miRNAs in the eradication of the BCSCs.[5][8] [13][14]

3.4. DYSREGULATION of MicroRNAs in the BCSCs

Epigenetic alteration of the genetic composition in the protein coding genes were implicated in cancer initiation and aggressiveness. The epigenetic mechanism involved in the miRNA dysregulation include the DNA methylation and histone acetylation that affect the gene transcription and expression. DNA methylation is involved in the loss of pluripotency in breast cancer stem cells and epigenetic reprogramming can be used to generate cancer stem cells by downregulating the gene for differentiation and upregulating the gene for the expression and proliferation. DNA methylation is associated with wingless related integration site (Wnt)/ β -catenin activation by the methylation of the promoter and silencing of the Wnt inhibitors in the breast cancers. Wnt/ β - catenin is involved in the differentiation and proliferation of the cancer stem cells. DNA methylation of the E-cadherin promoter recruits histone deacetylases (HDACs) and cause histone acetylation with silencing of the gene transcription. [14][15]

3.5. Mechanism of MicroRNA regulated BCSCs in the Aggressiveness, Metastasis and Prognosis of Breast Cancer

MiRNAs control gene expression by acting as an oncogenes or tumor suppressor genes.[3] The epigenetic mechanisms can be used for the regulation of miRNAs expression in the breast cancer and can be potentially targeted to reverse cancer progression. MiRNAs are involved in post-translational gene silencing of the target mRNAs, and this is important for stem cell

proliferation, differentiation, and apoptosis. They can be used to determine prognosis and predict breast cancer survival. MiRNAs can be used as a diagnostic tool due to their biostability that enable their detection in the blood.

MicroRNA expression in breast cancer cells is associated with the levels of the estrogen, progesterone and Her2/neu receptors in breast cancer patients. [50] The correlation of the expression of miRNAs to the level of hormone receptor can serve as a prognostic indicator of the patient response to breast cancer treatment. [68] The miRNAs suppress the estrogen receptor alpha (ER α) expression by binding with the 3' UTR of estrogen receptor 1 (ESR1) mRNA. The activation of ER α enhance the transcription of target gene that control the cancer formation including cell proliferation, differentiation, and survival. Most of the downregulated miRNAs in estrogen receptor positive (ER⁺) breast cancer are tumor suppressor gene miRNAs suppressing the cell proliferation and upregulation of the miRNAs can be used to prevent proliferation breast cancer cells.[51][52][58][63]

The overexpression or silencing of miRNAs can be useful in determination of the metastatic and invasive characteristic of breast cancer. This regulatory role of the miRNA's expressions on the breast cancer stem cells can be a potential therapeutic target for the destruction and the eradication of the cancer cells through the metastatic and self-renewal pathway by preventing the formation of the mammosphere.[30][68] They are involved in the progression of breast cancer.

Cyclin D1 induces secretion of miRNAs controlling cancer immune response and oncogenic miRNAs by binding to the Toll-like receptor 8 to activate the pro inflammatory metastatic response. Cyclin D1 regulate the secretion of P- element induced Wimpy testis (PIWI) by interacting with the RNAs to control the expansion of the stem cells and increasing the levels of PIWI. Thus, they interact with the RNAs (piRNAs) to control the expansion of stem cells and increase the level of PIWI member of Argonaute family in breast cancer.[53]

Hypoxia was found to promote cancer aggressiveness by increasing the resistance of cancer to treatment. Hypoxia promotes cancer cells invasiveness and migration C-MET gene expression, which reprogram and expand the cancer stem cells colonies. [63] The implication of the hypoxia in the breast cancer progression with increased incidence of death among patients. Hypoxia inducible factor 1 alpha (HIF-1 α) mediated hypoxic response and regulates the transcription of the genes in response to hypoxia. HIF-1 α promote cell survival by the activation of transcription gene suppressing the expression of E-cadherin resulting in the loss

of cell-cell interaction and EMT. HIF-1 α promotes apoptosis by increasing the expression of pro-apoptotic gene BCL2 or by the increase in the level of p53. [54][63]

The exposure of breast cancer cells to hydrogen peroxide (H₂O₂) free radicals resulted in an increase in the level of expression of ESA⁺, CD44⁺ and CD24⁻ resulting in the loss of stem cells ability to mammosphere and the ability to generates cancer colony. Hydrogen peroxide free radicals triggered by the p53 activation and promoting the p21 expression indicate the role of p53/p21 signaling pathway in the free radical induced senescence in the BCSCs. [54] Increase levels of HIF-1 α expression is associated with poor prognosis and more aggressive high grade poorly differentiated breast cancer. Many transcriptional genes are deregulated by hypoxia resulting in the cancer aggressiveness and some of these deregulated genes include VEGF-A, WNT1, SMAD4, NDRG2 and EGFR. [13][29][67][68]

The maintenance of low level of free radicals was found to be important for the cancer stem cells survival. Thus, it is critical to avoid generation of free radicals in the breast cancer stem cells to prevent loss of function and these findings suggest the therapeutic benefit of the reactive oxygen species in the development of novel drug that can be used to eradicate drug resistant cancer stem cells via induction of premature cell death. The maintenance of undifferentiated stem cells is associated with hypoxia to enhance self-renewal property of the stem cells and inhibit the stem cells differentiation.

4. FUTURE PERSPECTIVES

There are currently limited studies related to the regulatory roles of miRNAs on the BCSCs in breast cancer.[67][68] The source of circulating miRNAs in the body fluid are still obscured to the scientists, it is difficult to determine whether the circulating miRNAs expressions in the body fluid is tumor specific or product of the dead cells. Thus, experimental reliability assessment is required before circulating miRNAs can be used as a marker.

[65][66][67][68]More broad and extensive studies are needed to be conducted in establishing the significance of the regulatory expressions of microRNAs on BCSCs in the management of breast cancer. The better understanding of the mechanism of microRNAs expression and the regulatory roles on BCSCs can be applied in determining the prognosis and responsiveness of breast cancer to a novel treatment. [68] An efficient breast cancer therapy can be developed aiming at breast cancer stem cells destruction by using miRNA effective delivery and avoiding normal progenitor stem cells destruction.[59] The miRNAs expression can be used to determine the metastatic BCSCs for an efficient targeting mechanism and the identification

of these metastatic BCSCs can be useful in the determination of the breast cancer stage, prognosis, and the responsiveness to the novel treatment regimen for the breast cancer. [60][62][67][68]

5. CONCLUSION

Studies have shown the relationship between the expression of miRNAs and cancer behaviors. MicroRNAs have been shown to have association with cancer metastasis and aggressiveness. Breast cancer stem cells are responsible for the initiation, dissemination, and breast cancer resistance to the available treatment options. MicroRNAs are major regulators of breast cancer stem cells, and they would be an extremely useful for the treatment of breast cancer by targeting the BCSCs.

MicroRNAs regulatory effect on neovascularization, drug resistance, and metastasis microRNAs can be used as the predictive indicators in determining the prognosis of breast cancer following treatment. The miRNAs expression can be used to determine the metastatic BCSCs for an efficient targeting mechanism and identification of these metastatic BCSCs can be useful in the determining the cancer stage, prognosis, and the responsiveness to therapy.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

None

REFERENCES.

1. Duru, N., Fan, M., Candas, D., Mena, C., et. al. (2012). HER2⁺ associated radioresistance of breast cancer stem cells isolated from HER2⁻ negative breast cancer cells. *Clinical Cancer Research*, 18(24), 6634–6647.
2. Shimono, Y., Zabala, M., Cho, R. W., Lobo, N., Dalerba, P., et. al. (2009). Downregulation of miRNA-200c links breast cancer stem cells with normal stem cells. *Cell*, 138(3), 592–603.
3. Luwor, R. B., Baradaran, B., Taylor, L. E., et. al. (2013). Targeting Stat3 and Smad7 to restore TGF β cytotstatic regulation of tumor cells in vitro and in vivo. *Oncogene*, 32(19), 2433–2441.
4. Lee R.C. et. al. (1993). The *C. elegans* heterochromic gene in *Lin-4* encodes small RNAs with antiserum complementary to *Lin-14*. *Cel.* 75(5):843-54. Doi: 10.1016/0092-8674
5. Clarke, M. F., Dick, J. E., Dirks, P. B., et. al. (2006). Cancer stem cells—Perspectives on current status and future directions: AACR Workshop on cancer stem cells. *Cancer Research*, 66(19), 9339–9344.
6. Siahmansouri, H., Somi, M. H., Babaloo, Z., et. al. (2016). Effects of HMGA2 siRNA and doxorubicin dual delivery by chitosan nanoparticles on cytotoxicity and gene expression of HT-29 colorectal cancer cell line. *Journal of Pharmacy and Pharmacology*, 68(9), 1119–1130.
7. Gjerdrum, C., Tiron, C., Hoiby, T., et. al. (2010). Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. *Proceedings of the National Academy of Sciences*, 107(3), 1124–1129.
8. Al-Hajj, M., Becker, M. W., Wicha, M., et. al. (2004). Therapeutic implications of cancer stem cells. *Current Opinion in Genetics & Development*, 14(1), 43–47.
9. Kong, L.-M., Liao, C.-G., Zhang, Y., Xu, J., Li, Y., et. al. (2014). A regulatory loop involving miR-22, Sp1, and c-Myc modulates CD147 expression in breast cancer invasion and metastasis. *Cancer Research*, 74(14), 3764–3778.
10. Hartwig, F. P., Nedel, F., Collares, T., et. al. (2014). Oncogenic somatic events in tissue-specific stem cells: A role in cancer recurrence. *Ageing Research Reviews*, 13, 100–106.
11. Wang, R. A., Li, Z. S., Zhang, H. Z., Zheng, P. J., et. al. (2013). Invasive cancers are not necessarily from preformed in situ tumors—an alternative way of carcinogenesis

- from misplaced stem cells. *Journal of Cellular and Molecular Medicine*, 17(7), 921–926.
12. Yu, F., Yao, H., Zhu, P., Zhang, X., et al. (2007). Let -7 regulates self-renewal and tumorigenicity of breast cancer cells. *Cell*, 131(6), 1109–1123.
 13. Tang, J., Ahmad, A., et. al. (2012). The role of microRNAs in breast cancer migration, invasion and metastasis. *International Journal of Molecular Sciences*, 13(10), 13414–13437.
 14. Takahashi, R. □U, Miyazaki, H., et. al. (2014). The role of microRNAs in the regulation of cancer stem cells. *Frontiers in Genetics*, 4, 295.
 15. Gregory, P. A., Bert, A. G., Paterson, E. L., Barry, et. al. (2008). The miR □200 family and miR □205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. *Nature Cell Biology*, 10(5), 593–601.
 16. Ryu, S., McDonnell, K., Choi, H., Gao, D., Hahn, M., et. al. (2013). Suppression of miRNA □708 by polycomb group promotes metastases by calcium □induced cell migration. *Cancer Cell*, 23(1), 63–76.
 17. Pandey, D. P., & Picard, D. (2009). MiR □22 inhibits estrogen signaling by directly targeting the estrogen receptor α mRNA. *Molecular and Cellular Biology*, 29(13), 3783–3790.
 18. Kong, L. □M., Liao, C. □G., Zhang, Y., Xu, J., Li, Y., et. al. (2014). A regulatory loop involving miR □22, Sp1, and c □Myc modulates CD147 expression in breast cancer invasion and metastasis. *Cancer Research*, 74(14), 3764–3778.
 19. Frankel, L. B., Christoffersen, N. R., Jacobsen, A., et. al. (2008). Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR □21 in breast cancer cells. *Journal of Biological Chemistry*, 283(2), 1026–1033.
 20. Trivellin, G., Butz, H., Delhove, J., Igreja, S., et. al. (2012). MicroRNA miR □107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor □interacting protein in vitro. *American Journal of Physiology □Endocrinology and Metabolism*, 303(6), E708–E719.
 21. Moncini, S., Salvi, A., Zuccotti, P., Viero, G., et. al. (2011). The role of miR □103 and miR □107 in regulation of CDK5R1 expression and in cellular migration. *PLoS One*, 6(5), e20038
 22. Iorio, M. V., Casalini, P., Piovan, C., Di Leva, G., Merlo, A., et. al. (2009). microRNA □205 regulates HER3 in human breast cancer. *Cancer Research*, 69(6), 2195–2200.

23. Tavazoie, S. F., Alarcón, C., Oskarsson, T., Padua, D., Wang, Q., et. al. (2008). Endogenous human microRNAs that suppress breast cancer metastasis. *Nature*, 451(7175), 147–152.
24. Png, K. J., Yoshida, M., Zhang, X. H., Shu, W., Lee, H., et. al. (2011). MicroRNA miR-335 inhibits tumor reinitiation and is silenced through genetic and epigenetic mechanisms in human breast cancer. *Genes & Development*, 25(3), 226–231
25. Valastyan, S., Chang, A., Benaich, N., Reinhardt, F., et. al. (2010). Concurrent suppression of integrin $\alpha 5$, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. *Cancer Research*, 70(12), 5147–5154.
26. Cha, S.-T., Chen, P.-S., Johansson, G., Chu, C.-Y., Wang, et. al. (2010). MicroRNA miR-519c suppresses hypoxia-inducible factor-1 α expression and tumor angiogenesis. *Cancer Research*, 70(7), 2675–2685.
27. Xu, B., Zhang, X., Wang, S., et. al. (2018). MiR-449a suppresses cell migration and invasion by targeting PLAGL2 in breast cancer. *Pathology Research and Practice*, 214, 790–795.
28. El Helou, R., Pinna, G., Cabaud, O., Wicinski, J., Bhajun, R., et. al. (2017). miR-600 acts as a bimodal switch that regulates breast cancer stem cell fate through WNT signaling. *Cell Reports*, 18(9), 2256–2268.
29. Han, M.-l, Wang, F., Gu, Y.-t, Pei, X.-h, et. al. (2016). MicroR-760 suppresses cancer stem cell subpopulation and breast cancer cell proliferation and metastasis: By down-regulating NANOG. *Biomedicine & Pharmacotherapy*, 80, 304–310.
30. Schwarzenbacher, D., Balic, M., et. al. (2013). The role of microRNAs in breast cancer stem cells. *International Journal of Molecular Sciences*, 14(7), 14712–14723.
31. Liu, L., Zhou, W., Cheng, C.-T., Ren, X., Somlo, G., et. al. (2014). TGF β induces “BRCAness” and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes. *Molecular Cancer Research*, 12(11), 1597–1609.
32. Lowery, A. J., Miller, N., Dwyer, R. M., et. al. (2010). Dysregulated miR-183 inhibits migration in breast cancer cells. *BMC Cancer*, 10(1), 502.
33. Camps, C., Buffa, F. M., Colella, S., Moore, J., et. al. (2008). hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. *Clinical Cancer Research*, 14(5), 1340–1348.

34. Sasayama, T., Nishihara, M., Kondoh, T., et. al. (2009). MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. *International Journal of Cancer*, 125(6), 1407–1413.
35. Yang, J., Mani, S. A., et. al. (2006). Exploring a new twist on tumor metastasis. *Cancer Research*, 66(9), 4549–4552
36. Ma, L. (2010). Role of miR-10b in breast cancer metastasis. *Breast Cancer Research*, 12(5), 210.
37. Yan, L.-X., Huang, X.-F., Shao, Q., Huang, M.-Y., et. al. (2008). MicroRNA miR-21 overexpression in human breast cancer is associated with advanced clinical stage, lymph node metastasis and patient poor prognosis. *RNA*, 14(11), 2348–2360.
38. Selcuklu, S. D., Donoghue, M. T., et. al. (2009). miR-21 as a key regulator of oncogenic processes. *Biochemical Society Transactions*, 37(Pt 4), 918–925.
39. Huang, Q., Gumireddy, K., Schrier, M., Le Sage, C., et. al. (2008). The microRNAs miR-373 and miR-520c promote tumor invasion and metastasis. *Nature Cell Biology*, 10(2), 202–210.
40. Lambertini, E., Lolli, A., Vezzali, F., Penolazzi, L., et. al. (2012). Correlation between Slug transcription factor and miR-221 in MDA-MB-231 breast cancer cells. *BMC Cancer*, 12(1), 445.
41. Stinson, S., Lackner, M. R., Adai, A. T., Yu, N., et. al. (2011). miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. *Science Signaling*, 4(186), pt5–pt5.
42. Li, B., Lu, Y., Yu, L., Han, X., et. al. (2017). miR-221/222 promote cancer stem-like cell properties and tumor growth of breast cancer via targeting PTEN and sustained Akt/NF- κ B/COX-2 activation. *Chemico-Biological Interactions*, 277, 33–42.
43. Hemmatzadeh, M., Mohammadi, H., Jadidi-Niaragh, F., et. al. (2016). The role of oncomirs in the pathogenesis and treatment of breast cancer. *Biomedicine & Pharmacotherapy*, 78, 129–139.
44. Pedersen, I. M., Otero, D., Kao, E., Miletic, A. V., Hother, C., et. al. (2009). Onco-miR-155 targets SHIP1 to promote TNF α -dependent growth of B cell lymphomas. *EMBO Molecular Medicine*, 1(5), 288–295.
45. Asadzadeh, Z., Mohammadi, H., Safarzadeh, E., Hemmatzadeh, M., et. al. (2017). The paradox of Th17 cell functions in tumor immunity. *Cellular Immunology*, 322, 15–25.

46. Robertson, N. M., et. al. (2014). The role of microRNA in resistance to breast cancer therapy. *Wiley Interdisciplinary Reviews: RNA*, 5(6), 823–833.
47. Pileczki, V., Cojocneanu-Petric, R., Maralani, M., et. al. (2016). MicroRNAs as regulators of apoptosis mechanisms in cancer. *Clujul Medical*, 89(1), 50.
48. Bouchie, A. (2013). First microRNA mimic enters clinic. *Nature Research*, 31, 577–577.
49. Eto, K., Iwatsuki, M., Watanabe, M., Ida, S., et. al. (2014). The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab. *Annals of Surgical Oncology*, 21(1), 343–350
50. Sotiriou C. et. al. (2003). Breast Cancer Classification and Prognosis based on Gene Expression profiles from a population-based study. *Proc. Natl. Acad. Sci. USA* 101:2999-3004
51. Rajeev Kumar et. al. (2014). MicroRNA Regulates Estrogen Receptor Alpha in Breast Cancer metastasis. March 27, 2014. *Journal of Cancer Research and Therapy Oncology*.
52. Howard E.W. et.al. (2018). MicroRNA Regulation in Estrogen Receptor Positive Breast Cancer and Endocrine Therapy. *Biological procedures outlines*. 2018:20:17. Doi:10.1186/512575-018-0082-9
53. Zhao, J.-J., Lin, J., Yang, H., Kong, W., He, L., et. al. (2008). MicroRNA-221/222 negatively regulates estrogen receptor α and is associated with tamoxifen resistance in breast cancer. *Journal of Biological Chemistry*, 283(45), 31079–31086.
54. Xue, J., Chi, Y., Chen, Y., et. al. (2016). miRNA-621 sensitizes breast cancer to chemotherapy by suppressing FBXO11 and enhancing p53 activity. *Oncogene*, 35(4), 448–458.
55. Rucci, N., & Teti, A. (2010). Osteomimicry: How tumor cells try to deceive the bone. *Frontiers in Bioscience*, 2, 907–915.
56. Lin, X., Chen, W., Wei, F., Zhou, B. P., et. al. (2017). Nanoparticle delivery of miR-34a eradicates long-term-cultured breast cancer stem cells via targeting C22ORF28 directly. *Theranostics*, 7(19), 4805–4824.
57. Hui-Yi, Loh, Brendon, P. Norman et. al. (2019). The regulatory role of microRNAs in Breast Cancer. *Int. J. mol. Sci* 2019, 20 (19), 4940. Doi.org/10.3390/ijms20194940

58. Antonio Daniel Martinez-Gutierrez et. al. (2020). Identification of miRNA Master Regulator in Breast Cancer. *Cells* 2020, 9 (7), 1610. Doi.org/10.3390/cells9071610
59. Tong Niu et. al. (2021). MicroRNA Regulation of Cancer Stem Cells in the Pathogenesis of Breast Cancer. *Cancer Cell International* 21, Article number:31(2021)
60. Plabon Kumarr Das et. al. (2020). MicroRNAs, a Promising Target for Breast Cancer Stem Cells. *Molecular Diagnosis and Therapy* 24, 69-83
61. Nada Flores-Huerta et. al. (2021). LncRNAs and MicroRNAs as Essential Regulators of Stemness in Breast Cancer Stem Cells. *Biomolecules* 2021, 11(3), 380; Doi.org/10.3390/biom11030380
62. Yang, Z., Liu, Z et. al. (2020). The Emerging Role of MicroRNAs in Breast Cancer. Volume 2020/Article ID 9160905/Doi.org/10/1155/2020/916095
63. Saghar, Y, et. al. (2020). Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells. *Front. Oncol, Sec. Molecular and Cellular Oncology* Volume 10-2020. Doi.org/10.3389/fonc.2020.00452
64. El-Osaily, H. H et. al., (2021). Impact of miRNAs Expression Modulation on the Methylation Status of Breast Cancer Stem Cell Related Genes. *Clinical and Translational Oncology* 23, 1440-1451 (2021)
65. Duong T., et. al., (2022). Diagnostic and Prognostic Value of miR-200 Family in Breast Cancer: A Meta-analysis and Systematic Review. *Cancer Epidemiology* Volume 77, April 2022. 102097. Doi.org/10.1016/j.canep.2022102097
66. Ma, Y., Shen, N., et. al., (2021). The Roles of the Let-7 Family of MicroRNAs in the Regulation of Cancer Stemness. *Cells* 2021,10 (9), 2415; doi.org/10.3390/cells.10092415
67. Richard Vinita et. al., (2021). MicroRNAs in Molecular Classification and Pathogenesis of Breast Tumors. *Cancers* 2021,13(21),5332; doi.org/10.3390/cancers13215332
68. Rui Zhang et. al., (2022). Novel Molecular Regulators of Breast Cancer Stem Cell Plasticity and Heterogeneity. *Seminars in Cancer Biology*. Volume 82, July 2022, Pages 11-25. Doi.org/10.1016/j.semcaner.2021.03.008

